Maternal–fetal transport kinetics of methotrexate in perfused human placenta:In vitrostudy

Abstract

We report for the first time that the transport of methotrexate from maternal to fetal circulation is not negligible in human placenta at term. It is reasonable to assume that a direct risk for the fetus from methotrexate use in pregnancy cannot be excluded, and caution is warranted when it is used in emergency clinical situations.

Pregnancy associated breast cancer

“…Although chemotherapy is considered safe after the fi rst trimester, only few studies have investigated the long-term eff ect of in utero exposure. Some chemotherapeutic agents are known to cross the placental barrier such as cisplatin (16), cyclophosphamide (17), doxorubicine (18) and methotrexate (19). Methotrexate has been associated with malformations of the central nervous system, skeletal, gastrointestinal, and cardiac malformations, and even fetal death (20).…”

Transport kinetics of cisplatin in the perfused human placental lobulein vitro

“…The lobular perfusion technique has been used by our research group for the study of maternal-fetal exchange of diverse groups of drugs, including anticancer agents [9][10][11]. This method has the unique advantage of exploring transport across the placental membrane, under controlled experimental conditions, and independent of maternal and fetal hemodynamic and metabolic influences.…”

Toxicological Studies on The Effect of Methotrexate on Prenatal Rat Foetuses

“…MTX caused increasing apoptotic cells, delaying in Sphase, decreasing the number of mitotic cells and reduction in the number of cells of the foetuses of developing zebrafish (Lee et al, 2012). Also, it was found in the umbilical blood and placenta of a woman who received MTX causing foetal chromosomal aberrations (Al-Saleh et al, 2007). Studies in rats, mice, and rabbits revealed embryotoxicity and teratogenicity (Al-khateeb et al, 2014).…”